Classic Style Guide,Retatrutide

The retatrutide phase 3 trial start date is a pivotal point of interest for those tracking advancements in obesity and metabolic disorder treatments. While a single definitive "start date" for all retatrutide Phase 3 trials is complex due to the staggered nature of global clinical research, Eli Lilly has been actively enrolling participants and initiating various studies. The Eli Lilly retatrutide Phase 3 program is a multi-faceted endeavor, with several key trials underway and expected to yield significant results in the near future.

Eli Lilly, a renowned pharmaceutical company, is at the forefront of developing retatrutide, a novel triple G agonist. This investigational drug targets multiple receptors involved in appetite regulation and energy balance, including glucagon, GLP-1, and GIP. The TRIUMPH program represents Eli Lilly's commitment to thoroughly evaluating retatrutide's efficacy and safety across diverse patient populations. These Phase 3 studies are crucial for understanding the drug's long-term impact and its potential to revolutionize weight management.

Key Trial Information and Timelines:

Several Phase 3 trials are integral to the retatrutide development. For instance, one such trial (NCT05929066) focuses on evaluating the efficacy and safety of retatrutide in participants with obesity or overweight. The trial dates for specific studies vary. One notable study has trial dates ranging from March 5, 2025, to April 2028, with an expected duration of approximately 125 weeks. Another study, NCT05931367, is a Phase 3 investigation into the efficacy and safety of LY3437943 (the investigational name for retatrutide) once weekly, with a study duration of about 77 weeks.

The TRIUMPH-4 trial, for example, involved 445 participants aged over 18 and reported significant findings on December 11, 2025. This trial, along with others in the TRIUMPH program, is evaluating retatrutide for the treatment of obesity and related conditions like knee osteoarthritis. Lilly's first Phase III results for retatrutide have indeed shown unprecedented weight loss and marked reductions in osteoarthritis pain.

Retatrutide Phase 3 trial results are eagerly anticipated. Preliminary data from Eli Lilly has been highly promising. For instance, Lilly's triple G agonist, retatrutide, has demonstrated substantial weight loss. In the TRIUMPH-4 study, participants with obesity taking retatrutide 12 mg lost an average of 24.2% of their body weight. Furthermore, Lilly's phase 3 trial for type 2 diabetes patients, reported around March 19, 2026, showed an average weight loss of 16.8% and significant improvements in blood sugar control, with notable A1C dips.

Eli Lilly's commitment to this research is evident as they are currently conducting Phase 3 studies and have initiated further investigations. For example, a new Phase 3b Obesity study was formally launched on January 16, 2026, though its trial status was "not yet recruiting" at that time. Eli Lilly is investigating retatrutide in seven other Phase III trials, with readouts expected in 2026. The overall Phase III global registrational clinical development program is evaluating the safety and efficacy of retatrutide.

Understanding the Search Intent:

The search queries surrounding retatrutide phase 3 trial start date Eli Lilly reflect a strong intent to understand the current status and future prospects of this drug. Users are interested in the trial, its Trial Phase, specifically III, and the broader Trials being conducted. Information regarding 2026 is crucial, as this is a key year for expected results. The drug name, retatrutide, and the company, Eli Lilly, are central to all searches. Specific dates like December 11, 2025, and March 19, 2026, are important milestones. The term Phase 3 is consistently used, highlighting the advanced stage of development. User interest extends to Lilly's overall efforts, including the ability to Search Lilly clinical trials and understand when Eli Lilly will be currently conducting Phase 3 studies. Understanding Trial Dates and the duration of Lilly's Phase III trials is also a significant part of the user's intent. The desire to find retatrutide phase 3 trial results march 2026 and understand the Phase III progression is paramount. Ultimately, users want to know the time it